The 5 analysts offering 12-month price forecasts for Atara Biotherapeutics Inc have a median target of 4.80, with a high estimate of 28.00 and a low estimate of 0.50. The median estimate represents a +590.05% increase from the last price of 0.70.
The current consensus among 7 polled investment analysts is to Hold stock in Atara Biotherapeutics Inc. This rating has held steady since December, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.61
Reporting Date Feb 27
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.